Reach Us +447480022765
Trimethoprim-Sulfamethoxazole (TMP-SMX) Induced Severe Systemic Reaction | OMICS International | Abstract
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Trimethoprim-Sulfamethoxazole (TMP-SMX) Induced Severe Systemic Reaction

Farrukh Abbas1*, Mehul Patel1, Khuram Abbas2, Pulin Shah1and Michael N Gurel1

1Rochester General Hospital, Rochester, NY, USA

2Shalimar Hospital, Lahore, Pakistan

*Corresponding Author:
Farrukh Abbas
Rochester General Hospital, Rochester
Tel: 585-957-3160
E-mail: [email protected]

Received date: December 27, 2016; Accepted date: February 08, 2017; Published date: February 11, 2017

Citation: Abbas F, Patel M, Abbas K, Shah P, Gurel MN (2017) Trimethoprim- Sulfamethoxazole (TMP-SMX) Induced Severe Systemic Reaction. J Pulm Respir Med 6: 393. doi: 10.4172/2161-105X.1000393

Copyright: © 2017 Abbas F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Objective: Trimethoprim-Sulfamethoxazole (TMP-SMX) is a relatively commonly prescribed antibiotic. One of the rare but dramatic reactions to TMP-SMX is severe systemic reaction which can mimic sepsis or septic shock and this can be a diagnostic challenge especially in critical care setting. The objective is to raise information about this side effect. Study Selection: The case series includes two patients’ reports. The first patient was 85 year old woman who received TMP-SMX before dental extraction and presented with rash and fever. She met SIRS criteria with leukocytosis, bandemia, lactic acidosis and acute kidney injury. All the infectious work remained negative. She improved with supportive care. She received TMP-SMX again after a few weeks and again presented with similar clinical course. Again the infectious work up remained negative and she improved with supportive care. It was thought that TMP-SMX contributed to this. The second patient was 85 year old man who took TMP-SMX for right leg cellulitis and presented with systemic inflammatory response resembling septic shock. All the infectious work up remained negative. The patient recovered completely with supportive care. TMP-SMX was thought to be responsible for the side effect. Conclusion: TMP-SMX induced systemic reaction resembling anaphylaxis or sepsis is rare. Symptoms are very similar to classic sepsis and septic shock including fever, chills, leukocytosis and hemodynamic instability. This has been described mostly in HIV patients but this may happen in non-HIV patients as well.